Key result
The R133W beta-tropomyosin mutation was associated with lower specific force (P<0.05) and rate constant of force redevelopment (P<0.01), and faster maximum velocity of unloaded shortening (P<0.05).
Why the study?
Does the R133W beta-tropomyosin mutation alter the regulation of muscle contraction in single human muscle fibres?
Population
Single chemically skinned muscle fibres from two patients carrying the R133W beta-tropomyosin mutation and…
Comparison
R133W beta-tropomyosin (beta-Tm) mutation vs Healthy control subjects
Design
Preclinical
Authors
Loading...
May contribute to weakness via altered cross-bridge kinetics in R133W carriers; leaves open clinical relevance and therapeutic implications.
Case-Control
Does the R133W beta-tropomyosin mutation alter the regulation of muscle contraction in single human muscle fibres?
p-value: p=<0.05
The R133W beta-tropomyosin mutation alters myosin-actin kinetics, causing a reduced number of myosin molecules in the strong actin-binding state and resulting in muscle weakness.
Ochala et al. (2007) conducted a case-control in R133W β-tropomyosin mutation with muscle weakness. R133W beta-tropomyosin mutation vs. Healthy control subjects was evaluated on Specific force (SF), maximum velocity of unloaded shortening (V0), and apparent rate constant of force redevelopment (ktr) in type I fibres (p=<0.05). The R133W beta-tropomyosin mutation was associated with lower specific force (P<0.05) and rate constant of force redevelopment (P<0.01), and faster maximum velocity of unloaded shortening (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: